Moderna is a pioneering messenger in RNA therapeutics, an entirely new in-vivo drug modality that produces human proteins or antibodies inside patient cells that are, in turn, secreted or active intracellularly. This breakthrough platform addresses currently undruggable targets and offers a superior alternative to existing drug modalities for a wide range of disease conditions. Founded in late 2010 by Flagship VentureLabs, Cambridge-based Moderna is privately held and currently has strategic agreements with AstraZeneca and Alexion Pharmaceuticals.